ck18 as a biomarker in nash clinical trials
Published 4 years ago • 640 plays • Length 27:51Download video MP4
Download video MP3
Similar videos
-
10:02
leveraging pathophysiology and context of use to identify nash clinical trial biomarkers
-
1:01:13
biomarkers in nash drug development
-
38:02
nash globally: pathways to combination therapy, biomarkers and outcomes | arun sanyal
-
58:17
ask the experts nash and clinical trial
-
9:07
case study: discovery of an early diagnostic biomarker for nash
-
8:30
fruit worsens liver disease
-
17:30
treating nash 2023: current and near future treatments | ucla digestive diseases
-
26:47
fatty liver/nash what every patient needs to know by dr. robert gish
-
2:42
mayo clinic – nash clinical trial – a volunteer's plea
-
8:00
from nafld to nash: is inflammation the culprit?
-
3:32
nonalcoholic steatohepatitis (nash) | upmc on topic
-
22:31
making a diagnosis of non-alcoholic steatohepatitis (nash) | ucla digestive diseases
-
59:44
nonalcoholic fatty liver disease and cardiovascular risk
-
2:26:33
use of biomarkers for diagnosing and assessing treatment response in noncirrhotic nash trials-d2-am
-
49:01
outlook for nash therapy and market dynamics
-
10:24
noninvasive testing, candidate biomarkers in aatd-associated liver disease
-
54:09
the dawn of translation in nash and hepatic fibrosis
-
18:01
🔬unlocking the clinical chemistry in nafld|part 2: biomarkers, hepatic steatosis & nash
-
50:54
metabolomic approaches in nash and nafld r&d webinar | dec 2017
-
3:59
difference between nafld and nash | nafld vs nash
-
31:32
emerging therapies in nash
-
34:24
liver fibrosis | nash and nafld | the balance between formation and degradation in the ecm